SYRE250516P22500
- 0.00
- 0.000.00%
Spyre Therapeutics Newsroom
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $65
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Hold Rating
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Hold Rating
Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO), Spyre Therapeutics (SYRE) and Herbalife (HLF)
Spyre Therapeutics Analyst Ratings
Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target
Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target
Wolfe Research Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $27
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Hold Rating
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $65
Wedbush Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70
Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Spyre Therapeutics (SYRE)